Anti-Human SARM (CT)
| Code | Size | Price |
|---|
| LEI-S555-20ug | 20 ug | £199.00 |
Quantity:
| LEI-S555-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Application: Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:S558
Long Description:
Toll-like receptors (TLRs) are signaling molecules that recognize different microbial products during infection and serve as an important link between the innate and adaptive immune responses (1-3). SARM (SAM and ARM-containing protein), along with other molecules such as TIRP, TRIF, TIRAP, and MyD88, is thought to serve as an adaptor protein for the TLRs that allows for the activation of downstream kinases and NF-kB, and ultimately the expression of proteins involved in host defense (4,5). While SARM has not been conclusively
shown to associate directly with TLRs, the presence of a Toll-interluekin-1 (TIR) domain in SARM is consistent with a role as a signaling molecule (4,5).
Target:
SARM
References
1. Fenton, MJ. et al. (2003) Mol. Interv. 3:466-77. 2. Akira, S. et al. (2003) Annu. Rev. Immunol. 21:335-76. 3. Janeway Jr., CA. and Medzhitov, R. (2002) Annu. Rev. Immunol. 20:197-216. 4. Bowie, AG. et al. (2003) Trends in Imm. 24:286-9.
Related Products
| Product Name | Product Code | Supplier | SARM (CT) Blocking Peptide | LEI-S558 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|